NIIMBL Announces Action Plan for Increasing Flexibility of Antibody Manufacturing
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has released an action plan to enhance the flexibility of antibody manufacturing for rapid response. Next-generation technologies could accelerate production, speed market delivery, and expand treatment options for various diseases and variants. However, adoption remains challenging for the biopharmaceutical industry. To address this, NIIMBL gathered insights from industry experts through interviews, surveys, and workshops. The resulting plan outlines the benefits of advanced technologies, current barriers to adoption, and priority actions NIIMBL and the U.S. government can take to overcome these challenges.
NIIMBL Announces Action Plan for Increasing Flexibility of Antibody Manufacturing